Peripheral T-cell lymphoma, not otherwise specified is a heterogeneous group of aggressive neoplasms with indistinct borders. By gene expression profiling we previously reported unsupervised clusters of peripheral T-cell lymphomas, not otherwise specified correlating with CD30 expression. In this work we extended the analysis of peripheral T-cell lymphoma molecular profiles to prototypical CD30 + peripheral T-cell lymphomas (anaplastic large cell lymphomas), and validated mRNA expression profiles at the protein level. Existing transcriptomic datasets from peripheral T-cell lymphomas, not otherwise specified and anaplastic large cell lymphomas were reanalyzed. Twenty-one markers were selected for immunohistochemical validation on 80 peripheral T-cell lymphoma samples (not otherwise specified, CD30 + and CD30 -; anaplastic large cell lymphomas, ALK + and ALK -), and differences between subgroups were assessed. Clinical follow-up was recorded. Compared to CD30 -tumors, CD30
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+ peripheral T-cell lymphomas, not otherwise specified were significantly enriched in ALK -anaplastic large cell lymphoma-related genes. By immunohistochemistry, CD30
+ peripheral T-cell lymphomas, not otherwise specified differed significantly from CD30 -samples [down-regulated expression of T-cell receptor-associated proximal tyrosine kinases (Lck, Fyn, Itk) and of proteins involved in T-cell differentiation/activation (CD69, ICOS, CD52, NFATc2); upregulation of JunB and MUM1], while overlapping with anaplastic large cell lymphomas.
CD30
-peripheral T-cell lymphomas, not otherwise specified tended to have an inferior clinical outcome compared to the CD30 + subgroups. In conclusion, we show molecular and phenotypic features common to CD30 + peripheral T-cell lymphomas, and significant differences between CD30
-and CD30 + peripheral T-cell lymphomas, not otherwise specified, suggesting that CD30 expression might delineate two biologically distinct subgroups.
Introduction
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of clinically aggressive neoplasms, some of which constitute distinct clinicopathological entities, with more or less stringent diagnostic criteria. Still, the largest group of PTCL is represented by the "not otherwise specified" (NOS) category, characterized by unclear demarcations owing to pronounced morphological and immunophenotypic heterogeneity and absence of defining molecular criteria. 1 The CD30 antigen has historically been instrumental in defining anaplastic large cell lymphomas (ALCL) as a distinct category, characterized by a frequently cohesive and intrasinusoidal proliferation of large pleomorphic cells with strong and homogeneous expression of CD30. 2 The discovery of recurrent chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene in a subset of these lymphomas led to the delineation of ALK + and ALK -ALCL as two disease subtypes. 3, 4 Evidence of additional distinguishing clinical and biological features has more recently justified the recognition of ALK + ALCL as a discrete entity in the 2008 World Health Organization (WHO) classification, and the inclusion of ALK -ALCL as a provisional category. 1, [5] [6] [7] As defined in the WHO book, ALK -ALCL comprises CD30 + T-cell neoplasms that are not reproducibly distinguishable on morphological grounds from ALK + ALCL, but lack ALK gene rearrangement and expression, with most cases expressing T-cell-associated markers and cytotoxic granule-associated proteins. 1 In fact, the definitional criteria remain subject to variations in interpretation, and especially the criteria used for morphological assessment to consider "anaplastic" morphology may be subtle and frequently subjective. 1, 8, 9 In particular, a subset of PTCL, 19 The purposes of the present work were: (i) to extend this molecular characterization of PTCL to include ALCL cases, and more specifically to explore the molecular relationship between CD30 + PTCL, NOS and ALK -ALCL; (ii) to validate our previous GEP findings at the protein level, postulating the existence of significant differences in the protein expression profiles between CD30 + and CD30 -PTCL, NOS; and (iii) to examine clinical outcomes according to pathological classification and immunophenotypic subgroups.
Design and Methods

Gene expression analyses
In order to compare the expression profiles of 16 
19
; Lamant et al. 7 ), the RMA normalized matrices were averaged per gene symbol, concatenated and quantile-normalized. The four PTCL categories were compared for the expression of two gene sets, referred to as "CD30 neg. signature" (Table S4 of de Leval et al. 19 ) and "ALK neg. signature" (Table S3 of Lamant et al. 7 ). For each gene set, the mean expression across genes was calculated per sample and compared using Welch t tests. The "ALK neg. signature" was also used for gene set enrichment analysis (GSEA), as previously described. 19, 20 Validation of gene expression profiling data at the protein level Figure S1 ). CD30 -PTCL, NOS were all essentially negative for CD30. Approval for the study was obtained from the Ethics Committee of the University Hospital of Liège.
For immunohistochemical validation of GEP findings, the selection of markers was based on: (i) the most differentially expressed genes across distinct PTCL subgroups, according to our GEP datasets and other publicly available sources; 6, 7, 13, 19, [21] [22] [23] [24] (ii) their involvement in relevant cellular pathways; and (iii) availability of primary antibodies suitable for paraffin-embedded tissues. The Table S2 .
The immunolabeled sections were evaluated semi-quantitatively, using a scoring scale based on extent and intensity of the stainings. 25 The extent score and the intensity score were multiplied to provide a unique global score, ranging from 0 to 12, for each immunostain. Cases were considered positive for a marker when the corresponding global score was ≥4.
Clinical data
The clinical data recorded for each patient of the validation set included sex, age at diagnosis and date of the diagnostic biopsy. Clinical outcome was determined by overall survival and progression-free survival. 26 
Statistical analyses of clinical and immunohistochemical data
Differences in clinical features and immunostaining scores between the PTCL subgroups were assessed by means of the chi-square, Mann-Whitney and KruskalWallis tests (GraphPad Prism software, San Diego, CA, USA). Distributions of overall and progression-free survival were analyzed by the Kaplan and Meier method and compared using the log-rank test (GraphPad Prism software). 27, 28 Hierarchical cluster analysis was conducted on all immunohistochemical data (average linkage clustering, Cluster and TreeView softwares, http://www.eisenlab.org).
29,30
Results
Gene expression analyses reveal molecular similarities between CD30
+ peripheral T-cell lymphomas, not otherwise specified and ALK -anaplastic large cell lymphomas
In our previous work, comparison between the molecular signatures of six CD30
+ versus ten CD30 -PTCL, NOS revealed significant down-regulation of several genes involved in T-cell activation (comprising CD28, CD52 and CD69) and TCR signal transduction (including Lck, Fyn and Itk). 19 Here, we compared the level of expression of that set of genes (down-regulated in CD30
+ versus CD30 -PTCL, NOS, i.e. overexpressed in CD30 -versus CD30 + PTCL, NOS, referred to as the "CD30 neg. signature") in the four groups of PTCL. As seen in Figure 2A , the expression of those genes defining the "CD30 neg. signature" was also significantly down-regulated in ALCL (irrespective of ALK status) (Welch t test, P<2x10 -16 ). The levels of expression in ALCL were slightly lower than in CD30 + PTCL, NOS (P=0.0013).
Since the defective expression of TCR-related molecules has been suggested to be a distinguishing feature of ALCL, 21, 22 we wanted to specifically search for molecular similarities between CD30 + PTCL, NOS and ALK -ALCL. Thus, we looked at the expression of a set of genes defining the "ALK neg. signature" (up-regulated in ALK -ALCL compared to ALK + ALCL). As seen in Figure 2B , the expression levels of this gene set were slightly lower but not significantly different in CD30 + PTCL, NOS compared to ALK -ALCL (P=0.088), whereas they were significantly reduced in CD30 -PTCL, NOS (P=0.0002). Accordingly, GSEA using the "ALK neg. signature" showed significant enrichment for expression in the group of CD30 + PTCL, NOS as compared to CD30
-PTCL, NOS (141 genes; P=0.0415).
CD30 + peripheral T-cell lymphomas share common phenotypic features
A summary of the immunostaining results for the tested markers is provided in Table 1 , and the details of all immunohistochemical scores can be consulted in Online Supplementary Figure S2 and Online Supplementary Table S3. -PTCL, NOS (median 0; 23% positive). In contrast to the foregoing GEP prediction, 7 we did not observe a significant difference in MUM1 expression between ALK -(median 9.5; 100% positive) and ALK + ALCL (median: 6; 71% positive).
C/EBPβ and pSTAT3 were both highly up-regulated in ALK + ALCL (both medians 12; both 95% positive) compared to the other PTCL categories (medians for C/EBPβ: 0-2; medians for pSTAT3: 0-5.5). It was noteworthy that haematologica | 2013; 98(8) Figure S4 .
The differences observed between CD30 -PTCL, NOS and the various groups of CD30 + PTCL were to a large extent accounted for by molecules involved in proximal Tcell signaling (CD3, TCRβF1, ZAP-70, Lck, Fyn, Itk) and Tcell differentiation/activation (CD52, CD69, ICOS, NFATc2), the expression of which proved to be significantly reduced in all CD30 + samples. As predicted by our GEP findings, 19 most of these dissimilarities also pertained to the CD30 -versus CD30 + comparison within the PTCL, NOS group, while the CD30 + PTCL, NOS cases were not distinguishable from the ALCL samples on the basis of these pathways, except for a mostly retained expression of CD3.
CD30
+ and CD30 -peripheral T-cell lymphomas are segregated by hierarchical cluster analysis
Hierarchical clustering was performed starting from all immunohistochemical scores obtained with the 21 markers specifically explored in this study, including CD3 (Online Supplementary Table S2 Within the spectrum of CD30 + PTCL, ALK + ALCL tended to cluster together, distinguished by up-regulation of pSTAT3, C/EBPβ and cyclin D3, all described to be activated or induced by chimeric ALK. 32 Conversely, the two CD30 + ALK -PTCL categories (comprising NOS and ALCL cases) were mostly intermingled with one another, reflecting considerable similarities in their protein expression profiles. The levels of CD3, ZAP-70 and NFATc2 were generally higher in these samples than in ALK + ALCL. 
CD30 -peripheral T-cell lymphomas, not otherwise specified tend to have an inferior clinical outcome
Available clinical characteristics and survival data for the various PTCL subgroups are summarized in Table 2 . The median age of the ALK + ALCL patients (22 years) was significantly lower than that of the other categories (58-62 years; P<0.0001, Kruskal-Wallis test). A male predominance was observed in all subgroups (overall male:female ratio 1.47). The median follow-up time for all patients was 30 months (range, 1-153 months).
Overall and progression-free survival curves, stratified by diagnostic category, are illustrated in Online Supplementary Figure S5 . When comparing the median overall and progression-free survivals, ALK + ALCL tended to have a better outcome (medians not reached for ALK + ALCL). Conversely, patients with CD30 -PTCL, NOS were characterized by shorter median overall survival and progressionfree survival (24 and 10.5 months, respectively; compared to approximately 60 months for CD30 + PTCL, NOS and ALK -ALCL). However, none of the differences was statistically significant, either when comparing all four subgroups at once (P=0.252 for overall survival and P=0.186 for progression-free survival; log-rank Mantel-Cox tests), or when comparing the various subgroups in pairs (lowest P=0.053 for overall survival, when comparing ALK + ALCL and CD30 -PTCL, NOS; lowest P=0.081 for progressionfree survival, when comparing ALK + ALCL and CD30 -PTCL, NOS; log-rank Mantel-Cox tests).
Discussion
The present work was based on our previous observations suggesting conspicuous dissimilarities between the molecular profiles of PTCL, NOS according to CD30 expression. 19 Within the spectrum of PTCL, a diagnostic gray zone exists between PTCL, NOS and ALK -ALCL, accounted for by a subset of PTCL composed of large CD30 + cells. 1 To further explore the possible relatedness of CD30 + nodal PTCL at the molecular level, we extended here the analysis to a series of ALCL, and found substantial overlaps between the signatures of CD30 + PTCL, NOS and ALK -ALCL, while the profile of CD30 -samples was confirmed to be clearly divergent.
With the main purpose of corroborating transcriptional data at the protein level, we studied a larger series of CD30 -and CD30
+ PTCL (NOS type and ALCL) by immunohistochemistry, focusing primarily on those molecules whose expression had appeared to be discriminating between CD30 + and CD30 -PTCL, NOS subgroups. The CD30 + PTCL, NOS group featured a substantial loss of several molecules involved in TCR signaling and T-cell differentiation/activation (the proximal tyrosine kinases Lck, Fyn and Itk, the surface antigens CD69, CD52 and ICOS, and the transcription factor NFATc2), which were, in contrast, mostly conserved in CD30 -samples. Conversely, the transcription factors JunB and MUM1/IRF4 showed an opposite expression pattern, being highly expressed in most CD30 + PTCL, NOS and largely absent in the majority of CD30 -cases. Interestingly, by studying these same proteins in ALK + and ALK -ALCL samples, we observed expression scores that were strikingly similar to those of CD30 + PTCL, NOS.
In line with these observations, hierarchical clustering of the whole set of immunohistochemical scores segregated the samples into two groups according to the expression of CD30. Although the organization of the data was carried out blindly by the software without any a priori information ("unsupervised analysis"), the immunomarkers had been selected on the basis of their differential expression ("supervised approach"), consequently implying some bias by the marker selection itself. Nevertheless, the immunohistochemical clustering mirrors the GEP clustering somewhat and underscores distinctive immunophenotypic features between CD30 -PTCL, NOS and the whole group of CD30 + PTCL, independently of the commonly used diagnostic classifiers (namely ALK, CD30, EMA and cytotoxic proteins) which had been excluded from the analysis. The disturbed expression of molecules associated with the TCR/CD3 complex and downstream signaling previously evidenced in ALCL has been interpreted as a unifying feature of these neoplasms, irrespective of their ALK gene status, suggesting that this characteristic might enable ALCL to be distinguished from PTCL, NOS. 21, 22 However, the relationship between the down-regulation of TCRassociated molecules and the expression of CD30 has not been well characterized. Indeed, most PTCL, NOS cases included in those studies did not express CD30, and it could B. Bisig et al.
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haematologica | 2013; 98(8) not, therefore, be determined whether CD30 + PTCL, NOS would display features more similar to the remaining PTCL, NOS, or to the ALCL categories. Our findings establish that the defective expression of TCR-related signaling molecules is also a characteristic feature of CD30 + PTCL, NOS, thus pointing towards the impairment of TCR signaling as a pathway common to all CD30 + PTCL, including NOS cases, and raising consideration of whether the up-regulation of CD30 and disturbed expression of TCR-associated molecules might be mechanistically related. 33 
ALK
+ ALCL differed from other CD30 + PTCL by virtue of the up-regulation of several molecules known to be activated or induced by the kinase activity of ALK chimera. These comprised most notably the transcription factors pSTAT3 and C/EBPβ, and the cell cycle regulator cyclin D3. 6, 7, 13, 32, 34 Despite the limitations inherent to the selection of the markers studied, CD30 + PTCL, NOS and ALK -ALCL had markedly overlapping profiles, with differential expression of only two markers (CD3 and pSTAT3). Accordingly, in cluster analysis most CD30 + PTCL, NOS and ALK -ALCL samples clustered together. It could be opposed that the stringency of the criteria utilized for categorization as ALK -ALCL, which ensured that our ALK -ALCL group was strictly defined, might have led to some cases being classified as PTCL, NOS that others might consider consistent with ALK -ALCL. Indeed, six of the samples that we classified as PTCL, NOS had some hallmark-like cells, while not showing evidence of EMA and/or cytotoxic marker expression, hence not categorized as ALK -ALCL according to our criteria. Interestingly however, when we excluded these "borderline" samples from the analyses, only the score of pSTAT3 was significantly different between CD30 + PTCL, NOS and ALK -ALCL (data not shown), enabling us to exclude the hypothesis of an eventual bias introduced by the inclusion of these six cases. Moreover, when applying the molecular classifiers developed by Piva et al. 13 and Agnelli et al. 14 to discriminate ALCL from PTCL, NOS, we found that the levels of mRNA expression of three of the four genes which could be analyzed in our dataset (TMOD1, PERP, TNFRSF8) were significantly lower in CD30 + PTCL, NOS than in ALK -ALCL, while one of the genes (BATF3) was expressed at similar levels in CD30 + PTCL, NOS and ALCL. Interestingly, the levels of expression of TMOD1, PERP and TNFRSF8 were also significantly different between CD30 -and CD30 + PTCL, NOS, being lower in the CD30 -subgroup (data not shown). To what extent CD30 + PTCL, NOS and ALK -ALCL have overlapping and distinctive features remains to be characterized further. ALK -ALCL is currently considered a provisional entity, defined by often subtle morphological and immunophenotypic criteria. 1 The distinction from CD30 + PTCL, NOS, particularly from those cases composed of large pleomorphic cells, may be fragile and subjective. The molecular findings presented here further substantiate the biological continuum across CD30 + PTCL. From a clinical perspective, while it is well established that ALK + ALCL patients have a more favorable prognosis than patients with other systemic PTCL (although this difference may at least partially be dictated by the younger age at presentation), 5, 35 survival data are conflicting with regard to ALK -ALCL and PTCL, NOS. ten Berge et al. reported a comparable poor prognosis for these two entities (5-year overall survival: <45%), proposing that the segregation of the two entities might be of limited clinical relevance. 36 Conversely, in a larger study by the International Peripheral T-cell Lymphoma Project, ALK -ALCL patients had a significantly better outcome than PTCL, NOS patients (5-year overall survival: 49% versus 32%), with an even more marked difference when the analysis of PTCL, NOS was restricted to CD30 + cases (5-year overall survival: 19%). 5 The survival data available in the present study showed no significant differences between CD30 + PTCL, NOS and ALK -ALCL, but particularly for the latter category the cohort size was too small and the follow-up duration too limited to allow any significant conclusions to be drawn on this issue.
A more notable finding in our series, albeit not statistically significant, was the tendency of CD30 + PTCL, NOS patients to have a better outcome than those with CD30 -PTCL, NOS, suggesting that their segregation might be not only biologically but also clinically relevant, yet contrasting with the survival data reported by Savage et al. 5 Conversely, in a recent study from the North American T-cell lymphoma Consortium, describing the clinicopathological fea 37 The discordance in the outcome of the CD30 + PTCL, NOS cases between different studies remains unexplained. The fact that not all studies have used the same cutoffs for CD30 positivity, the retrospective nature of multicenter cohorts, the heterogeneity of the treatments delivered, and the relatively small numbers of patients are possible compounding factors that may account for the heterogeneous clinical outcomes. Altogether, however, the discordant observations emphasize the need to collect data from larger series of cases in a controlled setting.
In conclusion, following-up on previous GEP data our findings suggest that the expression of CD30 might constitute a valuable criterion to define two distinct biological subgroups (CD30 + and CD30 -) within the heterogeneous category of PTCL, NOS. The putative clinical relevance of these subgroups needs to be confirmed in larger series of patients, but might be reinforced by the potential benefits of incorporating anti-CD30 immunoconjugates into the treatment strategies of CD30 + PTCL. 
